Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Mar 3, 2009

Premium

Mort Minaee has joined 454 Life Sciences as head of regulatory affairs. He will be responsible for the regulatory approval process as the company prepares for the diagnostic use of the 454 sequencing technology.

Minaee comes to 454 from Abbott Molecular Diagnostics, where he was director of regulatory and clinical affairs. At Abbott, he worked with Roche and Genentech on a companion diagnostic for the cancer drug Tarceva. In the past, he held a position with Siemens Medical Solutions, where he obtained approvals for software-based diagnostic devices.


Illumina CEO Jay Flatley has joined the board of directors Helixis, a Carlsbad, Calif.-based developer of nucleic acid analysis tools. Prior to coming to Illumina, Flatley was president and CEO of Molecular Dynamics, now part of GE Healthcare, and led that company's initial public offering in 1993.


Mari Baker has left her post as CEO of Navigenics to take the chief executive position at video game company PlayFirst. She will have "ongoing board roles" at Navigenics and Cozi Group, according to PlayFirst.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.